RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > The WHO Certification Scheme and International Pharmaceutical Product Marketing

The WHO Certification Scheme and International Pharmaceutical Product Marketing

Posted 01 June 2008 | By

The World Health Organization (WHO) is the United Nations' leading regulatory authority for international public health. According to WHO, access to essential and quality medicines is a basic human right.1 Because of the unique way the pharmaceutical industry impacts human health and well-being, WHO plays an important role in regulating international drug approval and marketing. Quality, safety and efficacy (QSE) are the fundamental requirements for marketing a drug in any country. Any new drug must meet adequate quality standards and have sufficient clinical evidence to demonstrate its safety and effectiveness before it can enter the market.2 New drug approval is a highly complex process that requires a high level of expertise and resources, and large, well-trained, experienced multidisciplinary teams with the capability to review and evaluate all aspects of new products. Only a few regulatory agencies, mainly in welldeveloped, industrialized countries, are competent to effectively evaluate new drugs to assure their quality, safety and efficacy.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.